

# **Risk factors for frailty in older adults**

Xinrui Wang, MD<sup>a</sup>, Jiji Hu, MD<sup>a</sup>, Diping Wu, PhD<sup>a,\*</sup> 💿

## Abstract

**Aims:** To clarify the risk factors for frailty to help doctors prevent diseases that cause weakness, through early interventions.

**Methods:** We searched the PubMed, EMBASE, and Cochrane Library databases to identify all relevant studies using the items "frailty," "weak," "risk factors," and "predictive factors" and compared their results. The aging population (≥65 years old) was divided into 2 groups, a "frailty group" and a "robust control group," and then the characteristics, lifestyles, and comorbidities were compared.

**Results:** We compared the influence of baseline and concomitant diseases on frailty in the elderly respectively, and the analysis of the influence of baseline on frailty found that increasing age, lower weight, female sex, living alone, low levels of exercise, polypharmacy, higher education level, smoking, drinking, malnutrition, and lower vitamin D levels were associated with aging individuals being more likely to experience frailty. The data about concomitant diseases had shown that diabetes, hearing dysfunction, cognitive impairment, poor sleep, a history of falls, pain, and depression can increase the risk of frailty among the elderly population.

**Conclusion:** Characteristics, comorbidities, and lifestyle factors can impact the occurrence of frailty, and relevant influencing factors should be considered.

**Abbreviations:** BMI = body mass index, CI = confidence interval, RR = relative risk.

Keywords: ageing adults, frailty, meta-analysis, risk factors

## 1. Introduction

The ageing of the population worldwide is an important public health issue. The increasing frailty of elderly individuals that has accompanied this trend has become a major problem in the field of population ageing.<sup>[1]</sup> This is mostly because of the association of frailty with an increased risk of adverse health outcomes.<sup>[2,3]</sup> Physical frailty is a biological syndrome that reflects a diminished reserve to buffer against stressors due to deteriorating physiological systems that results in vulnerability to adverse health consequences and inducing cumulative decline in multiple physiologic systems and that has been associated with an increased risk of falls, disability, institutionalization, hospitalization, systemic diseases, and all-cause mortality.<sup>[1,4]</sup> In general, the definition of frailty is a condition of increased vulnerability to stressor events as a consequence of the cumulative decline in many physiological systems,<sup>[5]</sup> and the factors that can predict the occurrence of frailty deserve deep exploration.<sup>[4]</sup> Among numerous frailty-assessment tools, the most popular models are the physical frailty phenotype operationalized in 2001 by Fried et al<sup>[6]</sup> based on 5 frailty criteria, until Rockwood cumulative deficit model proposed, that is a frailty index based on a comprehensive geriatric assessment of individual deficits.<sup>[7]</sup> The definition used in this paper was based on the updated tool created by Rockwood and Mitnitski<sup>[7]</sup> in 2011. Several recent studies have identified severity of frailty across various conditions,

The authors have no funding and conflicts of interest to disclose.

\*Correspondence: Diping Wu, Department of Nursery, Gulin people's Hospital, Sichuan 646500, China (e-mail: diping\_wu@126.com).

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

including old age, female sex, and reduced concentration and motivation.<sup>[4,5,8-41]</sup> However, high-quality systematic reviews are still in demand. Overall, we conducted this project to study the risk factors for frailty.

## 2. Methods

#### 2.1. Ethical review

Ethical approval was not necessary, because this is a review.

#### 2.2. Search strategy and data extraction

This research of this systematic review was performed according to PRISMA checklist. We searched for articles published in recently decade (till January 2022), since we performed the definition of frailty proposed by Rockwood et al in 2011.<sup>[7]</sup> And the initial search process was designed to find all reports involving with the search terms: ("risk factors" OR "predictive factors") AND ("Frailty" OR "weak"). These searches were conducted in the following databases: PubMed, Web of Science, MEDLINE, EMBASE, and Google Scholar. A manual search was also performed to compensate for the deficiency of computer searches. The definition used in this paper was based on the updated tool created by Rockwood and Mitnitski<sup>[7]</sup> in 2011. Two authors independently screened all citations and abstracts identified by the search strategy to select potentially eligible studies. Data

http://dx.doi.org/10.1097/MD.000000000030169

The datasets generated during and/or analyzed during the current study are not publicly available, but are available from the corresponding author on reasonable request.

<sup>&</sup>lt;sup>a</sup> Department of Nursery, Gulin people's Hospital, Sichuan, China.

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Wang X, Hu J, Wu D. Risk factors for frailty in older adults. Medicine 2022;101:34(e30169).

Received: 10 February 2022 / Received in final form: 5 July 2022 / Accepted: 7 July 2022

were independently extracted by 2 authors using a predesigned data extraction Excel file. The inclusion criteria are: paper should with 2 groups: aging people ( $\geq 65$  years old) with frailty and without frailty (definition of frailty according to Rockwood and Mitnitski<sup>[7]</sup>); and the study contained in this project should present the data about baseline Characteristics and lifestyles of people, Comorbidities condition of people; all the definitions found for frailty were homogeneous in the selected articles. The exclusion criteria are: studies with redundant publications, reviews, unrelated topic, different frailty criteria, and different group settings.

#### 2.3. Comparisons and quality assessment

Finally, there are 36 studies<sup>[4,5,8-41]</sup> with 58,028 people included in this systematic-review. Data extraction included the baseline characteristics of aging adults, their lifestyle habits, their accompanying diseases, and whether they had experienced falls. And we evaluated 22 meta-analyses and compared 2 groups (frailty and healthy control groups) in each of the meta-analyses. The 22 meta-analyses included several risk factors including the following: age, body mass index (BMI), sex (female), living alone, low levels of exercise, polypharmacy (which was defined as not less than 5 kinds of oral prescription drugs<sup>[16]</sup>), the recorded number of drugs , education, smoking, drinking, malnutrition, vitamin D levels, and comorbidity (which was defined when the total number of recorded diseases of participant was greater than or equal to 2<sup>[12]</sup>). In addition, ten comorbid diseases were compared between people with frailty and those without frailty: stroke, cardiac disease, diabetes, vision dysfunction, hearing dysfunction, cognitive impairment, poor sleep, fall history, pain, and depression.

The quality of the included studies was assessed by 2 authors, according to the Cochrane Collaboration Reviewer's Handbook and the Quality of Reporting of Meta-analysis guidelines.<sup>[42,43]</sup>

#### 2.4. Data analysis

All of the final information was subsequently entered into Review Manager (RevMan) 5.1.4, which is Cochrane software for preparing and maintaining Cochrane reviews. It can perform meta-analysis of the data entered, and present results graphically. Continuous outcomes are presented as weighted mean differences with 95% confidence intervals (CIs). Dichotomous data are presented as relative risk (RR) with 95% CIs. The analysis of the meta-analyses was performed using the fixed-effects or random-effects method. The fixed-effects method was used to combine the results when no significant heterogeneity was present. The random-effects method was applied when heterogeneity was present. Statistical heterogeneity among the trials was evaluated using the  $I^2$  test (the iterative noncentral chi-square distribution method), with significance set at P < .05.

#### 3. Results

#### 3.1. Description of the included studies

A total of 3778 reports were initially identified from the database and manual search. At first step, 3565 reports were excluded from the study for the following reason: redundant publications, reviews, unrelated topic. After referring to the full text, 95 articles with different frailty criteria, and 82 articles with different group settings were excluded. We eventually included 36 papers for this research.<sup>[4,5,8-41]</sup> The conditions in these studies and the clinical details of the patients are presented in Table 1. The search flow diagram is presented in Figure 1.

## 3.2. Characteristics and lifestyles of people with/without frailty

First, we compared higher age, higher BMI, sex (female), living alone, low levels of exercise, polypharmacy, low level education, smoking, drinking, malnutrition and lower vitamin D levels among ageing people (Fig. 2A-M). Older people (RR: 0.96, 95% CI: 0.89–1.03, P < .001; Fig. 2A), lower BMI (RR: -0.55, 95% CI: -0.83- to 0.27, P < .001; Fig. 2B), female sex (RR: 1.16, 95% CI: 1.14–1.18, P < .001; Fig. 2C), single (RR: 1.62, 95% CI: 1.56–1.69, P < .001; Fig. 2D), low levels of exercise (RR: 1.41, 95% CI: 1.31–1.53, P < .001; Fig. 2E), polypharmacy (RR: 1.72, 95% CI: 1.17–2.28, *P* < .001; RR: 1.49, 95% CI: 1.39–1.60, P < .001; Fig. 2F, G), smoking (RR: 1.18, 95%) CI: 1.10–1.27, P < .001; Fig. 2J), drinking (RR: 0.78, 95% CI: 0.66-0.91, P = .002; Fig. 2K), malnutrition (RR: 2.11, 95%) CI: 1.74–2.57, P < .001; Fig. 2L), and lower vitamin D levels (RR: -3.22, 95% CI: -3.86 to 2.59, P < .001; Fig. 2M) were associated with frailty. The association between education level and frailty remains inconsistent: a longer education duration

Table 1	
	of included

Summary of included papers.

Author	Year	Included number	Research type
Arts	2021	378	Retrospect study
Ayesta	2021	98	Retrospect study
Brutto	2020	248	Retrospect study
Chen	2021	85	Retrospect study
Fan	2020	454	Retrospect study
Gilmore	2021	319	Retrospect study
Gomes	2018	804	Retrospect study
Henchoz	2017	634	Retrospect study
Hong	2019	299	Retrospect study
Ikeda	2019	25,549	Retrospect study
Jang	2021	2340	Retrospect study
Jiao	2020	9996	Retrospect study
Jung	2020	2907	Retrospect study
Kim	2021	252	Retrospect study
Kume	2021	150	Retrospect study
Lee	2014	1104	Retrospect study
Lee	2021	3040	Retrospect study
Liang	2021	179	Retrospect study
Liu	2021	7442	Retrospect study
McKechnie	2021	981	Retrospect study
Moradell	2021	33	Retrospect study
Okamura	2021	1565	Retrospect study
Oyon	2021	338	Retrospect study
Ozsoy	2021	166	Retrospect study
Poli	2017	361	Retrospect study
Rizka	2021	214	Retrospect study
Setiati	2021	888	Retrospect study
Sharma	2021	243	Retrospect study
Tamayo	2017	284	Retrospect study
Tang	2021	345	Retrospect study
Valdiviesso	2021	58	Retrospect study
Wang	2021	2363	Retrospect study
Xu	2021	642	Retrospect study
Yang	2018	147	Retrospect study
Yuan	2021	4894	Retrospect study
Zhao	2021	452	Retrospect study




Figure 1. Flowchart of literature review and reasons for exclusion.

decreased the risk of frailty (RR: -1.82, 95% CI: -2.40 to 1.24, P < .001; Fig. 2H), while the population that completed the mandatory education was more likely to become frail (RR: 1.12, 95% CI: 1.11–1.13, P < .001; Fig. 2I).

#### 3.3. Comorbidities of people with/out frailty


The comorbidities and comorbid diseases were compared (Fig. 3A-K). Even though comorbidities can actually impact the risk of frailty (RR: 1.66, 95% CI: 1.58–1.74, P < .001; Fig. 3A), not all of the conditions mentioned above affected frailty. Stroke (RR: 1.06, 95% CI: 0.99–1.14, P = .10; Fig. 3B), cardiac disease (RR: 1.00, 95% CI: 0.92-1.09, P = .95; Fig. 3C) and vision dysfunction (RR: 1.14, 95% CI: 0.88-1.48, P = .31; Fig. 3E) were not significantly different between the 2 groups. However, diabetes (RR: 1.10, 95% CI: 1.01-1.20, P = .04; Fig. 3D), hearing dysfunction (RR: 1.90, 95% CI: 1.38-2.61, P < .001; Fig. 3F), cognitive impairment (RR: 2.32, 95% CI: 2.10-2.56, *P* < .001; Fig. 3G), poor sleep (RR: 1.71, 95% CI: 1.55–1.89, P <.001; Fig. 3H), fall history (RR: 2.41, 95% CI: 2.02-2.88, P <.001; Fig. 3I), pain (RR: 1.65, 95% CI: 1.56–1.74, P < .001; Fig. 3J) and depression (RR: 3.47, 95% CI: 3.06–3.95, P < .001; Fig. 3K) can increase the risk of frailty among ageing people, respiratory disease (RR: 1.41, 95% CI: 1.20–1.66, P < .001; Fig. 3L).

#### 4. Discussion

Frailty is a very large challenge that occurs with a rapidly expanding older population. The overall prevalence of frailty in this community-dwelling population was 6.9%; frailty increased with age and was greater in female than in male. Four-year incidence under the frailty circumstance was 7.2%.<sup>[18]</sup> It was characterized by increased vulnerability to stressors following an

acceleration in the gradual decrease in physiological function, and it can impose a heavy burden on frail older adults, care professionals, and healthcare systems.<sup>[6,15,44]</sup> Therefore, several clinical guidelines for frailty management have suggested that modifiable risk factors for frailty, such as unhealthy diet and insufficient physical activity, should be addressed earlier.<sup>[36]</sup> The aim of this study was to evaluate the associations among frailty and basic characteristics, lifestyle factors, and comorbidities, with a specific focus on preventing the serious consequences of frailty. The collection of studies included in this systematic review contained a large and representative sample of community-dwelling older people.

According to our results, frailty was associated with older age, lower BMI, female sex, living alone, low levels of exercise, polypharmacy, smoking status, drinking status, low vitamin D levels, and malnutrition. These factors have been reported in several papers. The association with higher education level was controversial, as a longer period of education can decrease the likelihood of frailty (P <.001), while the population that completed the mandatory education was more likely to become frailty. However, the definition of mandatory is found to be different among several reports. Therefore, we assume that education time may decline frailty rate. Education is a social factor, and studies have only recently demonstrated the influence of social factors in the onset of frail conditions rather than limiting the approach to frailty to within a biological framework.<sup>[45,46]</sup> In particular, among the different lifestyle factors, we still know very little about cultural/social influences. Thus, identifying this factor and its potential role in the pathophysiology of frailty becomes of great importance to establish multidimensional models of prevention and treatment. This may help us understand the relationship between frailty and education level. In summary, this issue deserves further exploration in the future.



In addition to the physiological vulnerability caused by ageing, older adults who live alone are often vulnerable in terms of physical and psychosocial aspects.<sup>[47]</sup> Living alone is an important question that people face, and it is increasing year after year. Compared to those who live with their spouse or children, older adults who live alone have been associated with a lower economic status, a higher prevalence of chronic diseases, multimorbidity, depressive symptoms, and a higher percentage of safety incidents (falls and abuse).<sup>[47]</sup> For those reasons, older adults living alone are more vulnerable to physical, mental, and social impacts on health, which highlights the need for societal attention and support to help them maintain multilateral aspects of health and function as well as their independence.<sup>[47]</sup>

There are several previously published meta-analysis reports which all discussed the risk factors of frailty, but they focused only on the risk factors for frailty in specific populations. For instance, the research of Burton et al<sup>[48]</sup> only focused on the risk factors of frailty in acute stroke, and they only include 14 papers. The paper of Gallo et al<sup>[49]</sup> only focused on the risk factors of frailty in plastic surgery, and the study of Liu et al<sup>[50]</sup> only focused on the preoperative and postoperative delirium. While the report of Hajek et al<sup>[51]</sup> only contained the personality factors, we also include the effects of concomitant diseases on weakness. Above all, we have focused on risk factors for frailty in all elderly populations, which may help to better monitor the health of elderly patients; this is our advantage. However, some limitations must also be mentioned. First, the sociological factors affecting Frailty

а					g
Comorbidi	tv				Cognitive impair
	<ul> <li>Franty</li> </ul>	Non-frailty	Risk Ratio	Risk Ratio	Frailty
Study or Subgroup Fan 2020	Events Total		ght M-H, Fixed, 95% CI .1% 1.37 [1.25, 1.51]	M-H, Fixed, 95% CI	Study or Subgroup Events
Liu 2021	2904 4881		.4% 1.88 [1.77, 2.00]		Jiao 2020 521
McKechnie 2021	72 91	605 890 7	.0% 1.16 [1.04, 1.31]		McKechnie 2021 9 Rizka 2021 20
Rizka 2021	75 99		.3% 1.53 [1.23, 1.90]		Rizka 2021 20 Setiati 2021 24
Xu 2021	181 251 13 23		.3% 1.12 [1.01, 1.25]	-	Sharma 2021 40
Yang 2018	13 23	99 124 1	.9% 0.71 [0.49, 1.02]		Yuan 2021 466
Total (95% CI)	5530	4347 100	.0% 1.66 [1.58, 1.74]	•	Zhao 2021 165
Total events	3414	2001			Total (95% CI)
		$(P < 0.00001); I^2 = 9$	6%		Total events 1245
Test for overall effe	ct: $Z = 21.16 (P < $	0.00001)			Heterogeneity: Chi <sup>2</sup> = 42.48, df
b					Test for overall effect: Z = 16.38
Stroke	Frailty	Non-frailty	Risk Ratio		h
Study or Subgroup			ight M-H, Fixed, 95% CI		Poor sleeping
Ayesta 2021 Brutto 2020	1 12 8 91		2.30 [0.29, 18.13] 2.5% 1.91 [0.92, 3.94]		Frailty
kume 2021	3 21		.9% 0.66 [0.20, 2.22]		Study or Subgroup Events
McKechnie 2021	12 122		.3% 1.52 [0.73, 3.18]		Brutto 2020 30
Okamura 2021	4 30		.4% 1.30 [0.41, 4.09]		Fan 2020 132
Oyon 2021	9 68 149 165	8 180 1 1279 1400 89	.4% 2.98 [1.20, 7.40] 0.1% 0.99 [0.94, 1.04]		Lee 2014 92
Valdiviesso 2021	149 165	1279 1400 85	0.1% 0.99 [0.94, 1.04]		Tamayo 2017 20
Total (95% CI)	509	2929 100	0.0% 1.06 [0.99, 1.14]		Tang 2021 67
Total events	186	1362			Wang 2021 166
Heterogeneity: Chi <sup>2</sup>	= 16.34, df = 6 (	$P = 0.01$ ; $I^2 = 63\%$			Total (95% CI)
Test for overall effe	ct: $Z = 1.65 (P = 0)$	0.10)			Total events 1587
Cardiaa di					Heterogeneity: Chi <sup>2</sup> = 31.27, df
Cardiac di	Frailty	Non-frailty	Risk Ratio		Test for overall effect: Z = 10.90
Study or Subgrou	Events Total		ight M-H, Fixed, 95% Cl		1
Hong 2019	2 12		1.3% 0.82 [0.22, 3.04]		Fall history Frailty
kume 2021	4 91	31 890	1.6% 1.26 [0.46, 3.50]		Study or Subgroup Events
McKechnie 2021 Okamura 2021	18 122 134 165		4.6% 1.39 [0.78, 2.46] 0.3% 0.97 [0.90, 1.05]		Hong 2019 44
Ovon 2021	90 159		3.2% 1.02 [0.83, 1.24]	<b>1</b>	Ozsoy 2021 25
					Setiati 2021 58 Xu 2021 93
Total (95% CI)	549		0.0% 1.00 [0.92, 1.09]	•	XU 2021 93
Total events Heterogeneity: Chi <sup>2</sup>	248	1333			Total (95% CI)
. Test for overall effe					Total events 220
d	CC 2 = 0.00 (r = 1	0.55)			Heterogeneity: Chi <sup>2</sup> = 13.21, df Test for overall effect: Z = 9.78 (
Diabetes	Frailty	Non-frailty	Risk Ratio		lest for overall effect. Z = 9.78
Study or Subgroup			ight M-H, Fixed, 95% CI		Pain
Oyon 2021	6 30	14 68	2.4% 0.97 [0.41, 2.28]		Frailty
Ozsoy 2021	136 165		0.3% 0.99 [0.92, 1.06]	•	Study or Subgroup Events 1
Valdiviesso 2021 Hong 2019	20 57 2 12		5.9% 1.09 [0.70, 1.71] 1.0% 1.10 [0.29, 4.12]		Liu 2021 3061 4 McKechnie 2021 54
Avesta 2021	19 159		1.10 [0.29, 4.12]		MCKechille 2021 54
kume 2021	18 91		5.6% 1.41 [0.90, 2.20]	+	Total (95% CI) 4
McKechnie 2021	5 21		1.76 [0.58, 5.39]		Total events 3115
Okamura 2021	36 122	35 216	7.2% 1.82 [1.21, 2.74]		Heterogeneity: Chi <sup>2</sup> = 5.70, df = Test for overall effect: Z = 18.66
Total (95% CI)	657	2998 10	0.0% 1.10 [1.01, 1.20]	•	
Total events	242	1418		ľ	ĸ
Heterogeneity: Chi <sup>2</sup>	= 15.58, df = 7 (	$P = 0.03$ ; $I^2 = 55\%$			Depression
Test for overall effe	ct: Z = 2.10 (P = )	0.04)			Frailty
е					Study or Subgroup Events T Brutto 2020 0
Vision dys	sfunction				Gilmore 2021 77
	Frailty	Non-frailty	Risk Ratio		Henchoz 2017 11
Study or Subgrou			ight M-H, Fixed, 95% CI		kume 2021 54
Jiao 2020	539 385		Not estimable		Liu 2021 23 Rizka 2021 1039 4
Zhao 2021	102 272	59 180 10	0.0% 1.14 [0.88, 1.48]	<b>—</b>	Setiati 2021 64
Total (95% CI)	657	1217 10	0.0% 1.14 [0.88, 1.48]	•	Zhao 2021 30
Total events	641	1722		Ť	
Heterogeneity: Not					Total (95% CI) 5 Total events 1298
Test for overall effe	ect: $Z = 1.02$ (P =	0.31)			Total events 1298 Heterogeneity: Chi <sup>2</sup> = 32.89, df =
f					Test for overall effect: Z = 19.09
Hear dysf	unction				
near uysi					1
Study - Cat	Frailty	Non-frailty	Risk Ratio		1
Study or Subgrou Jiao 2020	ap Events Tota 484 38		eight M-H, Fixed, 95% CI Not estimable	-	Respiratory dis
Zhao 2020	484 38				Frailty
					Study or Subgroup Events
Total (95% CI)	65		0.0% 1.90 [1.38, 2.61]	◆	Ayesta 2021 8
Total events Heterogeneity: No	593	1493			Jung 2020 4 kume 2021 2
	t applicable fect: Z = 3.96 (P <	0.0001)		-10 -5 0 5 10	Sharma 2021 2 Sharma 2021 37
reactor overall er				Favours [Frailty] Favours [Non-frailty]	Zhao 2021 150
					Total (95% CI)
					Total events 201

Study or Subgroup		ty	Non-fr			Risk Ratio	Risk Ratio
	Events		Events		Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
iao 2020	521	385	1413	1037		Not estimable	
McKechnie 2021	9	91	55	890	2.6%	1.60 [0.82, 3.13]	
Rizka 2021	20	99	26	115	6.2%	0.89 [0.53, 1.50]	
Setiati 2021	24	170	78	718	7.7%	1.30 [0.85, 1.99]	+
Sharma 2021	40	149	6	94	1.9%	4.21 [1.86, 9.53]	
ruan 2021	466	1444	499	3450	76.2%	2.23 [2.00, 2.49]	
Zhao 2021	165	272	17	180	5.3%	6.42 [4.05, 10.20]	
Fotal (95% CI)		2610			100.0%	2.32 [2.10, 2.56]	
Total events	1245		2094			2.52 [2.10, 2.50]	•
Heterogeneity: Chi <sup>2</sup> = Test for overall effect					= 88%		
Poor sleep	ina						
	Frail	ty	Non-fr			Risk Ratio	
Study or Subgroup	Events	Total	Events			M-H, Fixed, 95% CI	
Brutto 2020	30	68	44	180	6.5%	1.80 [1.25, 2.62]	· · · · ·
Fan 2020	132	185	79	269	17.3%	2.43 [1.98, 2.99]	-
iao 2020	1080	385	3305	1037		Not estimable	
Lee 2014	92	142	870	1985	31.1%	1.48 [1.30, 1.69]	•
Tamayo 2017	20	63	82	221	9.7%	0.86 [0.57, 1.28]	-
Tang 2021	67	140	69	205	15.0%	1.42 [1.10, 1.84]	-
Wang 2021	166	1249	72	1114	20.4%	2.06 [1.58, 2.68]	-
	200						
Total (95% CI)		2232		5011	100.0%	1.71 [1.55, 1.89]	•
Total events	1587		4521				
Heterogeneity: Chi <sup>2</sup> =		f = 5 (		001); I <sup>2</sup>	= 84%		
Test for overall effect	: Z = 10.9	90 (P <	0.00001	0			
Fall history	,						
	Fian		Non-fr	ailty		Risk Ratio	
Study or Subgroup	Events					M-H, Fixed, 95% CI	
Hong 2019	44	159	19	140	17.3%	2.04 [1.25, 3.32]	
Dzsoy 2021	25	57	29	109	17.1%	1.65 [1.07, 2.53]	
Setiati 2021	58	170	124	718	40.7%	1.98 [1.52, 2.57]	-
Ku 2021	93	251	37	391	24.8%	3.92 [2.77, 5.54]	
Total (95% CI)		637		1358	100.0%	2.41 [2.02, 2.88]	•
Total events	220		209				
Heterogeneity: Chi <sup>2</sup> =	13.21, d	1 = 3 (1	= 0.004	4); l° = ;	11%		
Test for overall effect	: Z = 9.78	s (P < 0	.00001)				
Pain	Emili	N.	Non-fr	nilta		Risk Ratio	
itudy or Subgroup	Frail: Events	Total			Weight	M-H, Fixed, 95% CI	
and a subgroup					94.4%		·
	3061	4881	962	2558			
	3061 54	4881 91	962 400	2558 890	94.4% 5.6%	1.67 [1.58, 1.76]	
Liu 2021 McKechnie 2021		91		890	5.6%	1.32 [1.10, 1.59]	
	54		400	890			<b>-</b>
McKechnie 2021 <b>Total (95% CI)</b> Total events	54 3115	91 <b>4972</b>	400 1362	890 3448	5.6% 100.0%	1.32 [1.10, 1.59]	
McKechnie 2021 <b>Total (95% CI)</b> Total events Heterogeneity: Chi <sup>2</sup> =	54 3115 5.70, df	91 <b>4972</b> = 1 (P	400 1362 = 0.02);	890 3448 I <sup>2</sup> = 825	5.6% 100.0%	1.32 [1.10, 1.59]	•
McKechnie 2021 <b>Total (95% CI)</b> Total events	54 3115 5.70, df	91 <b>4972</b> = 1 (P	400 1362 = 0.02);	890 3448 I <sup>2</sup> = 825	5.6% 100.0%	1.32 [1.10, 1.59]	
McKechnie 2021 <b>Total (95% CI)</b> Total events Heterogeneity: Chi <sup>2</sup> =	54 3115 5.70, df	91 <b>4972</b> = 1 (P	400 1362 = 0.02);	890 3448 I <sup>2</sup> = 825	5.6% 100.0%	1.32 [1.10, 1.59]	•
McKechnie 2021 Fotal (95% CI) Fotal events Heterogeneity: Chi <sup>2</sup> =	54 3115 5.70, df Z = 18.6	91 4972 = 1 (P 66 (P <	400 1362 = 0.02); 0.00001	890 3448 I <sup>2</sup> = 825	5.6% 100.0%	1.32 (1.10, 1.59) 1.65 (1.56, 1.74)	-
McKechnie 2021 <b>Fotal (95% CI)</b> Fotal events feterogeneity: Chi <sup>2</sup> = Fest for overall effect <b>Depression</b>	54 3115 5.70, df Z = 18.6	91 4972 = 1 (P 56 (P <	400 1362 = 0.02); 0.00001 Non-fra	890 3448 I <sup>2</sup> = 825 ) ailty	5.6% 100.0%	1.32 [1.10, 1.59] 1.65 [1.56, 1.74] Risk Ratio	
McKechnie 2021 <b>rotal (95% CI)</b> Fotal events Heterogeneity: Chi <sup>2</sup> = Fest for overall effect <b>Depression</b> <b>itudy or Subgroup</b>	54 3115 5.70, df Z = 18.6	91 4972 = 1 (P 66 (P <	400 1362 = 0.02); 0.00001	890 3448 I <sup>2</sup> = 825 ) ailty	5.6% 100.0%	1.32 (1.10, 1.59) 1.65 (1.56, 1.74)	
McKechnie 2021 Total (95% CI) Total events Teeterogeneity: Chi <sup>2</sup> = Test for overall effect Depression Study or Subgroup Irutto 2020	54 3115 5.70, df Z = 18.6 Frail Events 0	91 4972 = 1 (P 66 (P < y Total 12	400 1362 = 0.02); 0.00001 Non-fra Events 0	890 3448 1 <sup>2</sup> = 825 ) ailty Total 138	5.6% 100.0% % Weight	1.32 [1.10, 1.59] 1.65 [1.56, 1.74] Risk Ratio M-H, Fixed, 95% CI Not estimable	-
McKechnie 2021 Total (95% CI) Total events teterogeneity: Chi <sup>2</sup> = Fest for overall effect Depression titudy or Subgroup trutto 2020 Jimore 2021	54 3115 5.70, df Z = 18.6 Frail Events 0 77	91 4972 = 1 (P 66 (P < y Total 12 176	400 1362 = 0.02); 0.00001 Non-fra Events 0 11	890 3448 1 <sup>2</sup> = 825 ) ailty <u>Total</u> 138 143	5.6% 100.0% % Weight 4.2%	1.32 [1.10, 1.59] 1.65 [1.56, 1.74] Risk Ratio M-H, Fixed, 95% CI Not estimable 5.69 [3.15, 10.28]	
McKechnie 2021 Total (95% CI) Total events Heterogeneity: Chi <sup>2</sup> = Fest for overall effect Depression Study or Subgroup Irutto 2020 Jilmore 2021 Jenchoz 2017	54 3115 5.70, df Z = 18.6 Frail Events 0 77 11	91 4972 = 1 (P 6 (P < y Total 12 176 68	400 1362 = 0.02); 0.00001 Non-fra Events 0 11 15	890 3448 1 <sup>2</sup> = 825 ) ailty Total 138 143 180	5.6% 100.0% % Weight 4.2% 2.8%	1.32 [1.10, 1.59] 1.65 [1.56, 1.74] Risk Ratio M-H, Fixed, 95% CI Not estimable 5.69 [3.15, 10.28] 1.94 [0.94, 4.01]	
McKechnie 2021 Fotal (95% CI) Fotal events deterogeneity: Chi <sup>2</sup> = Fest for overall effect Depression ktudy or Subgroup routs 2020 allmore 2021 tenchoz 2017	54 3115 5.70, df Z = 18.6 Frailt Events 0 77 11 54	91 4972 = 1 (P 66 (P < y Total 12 176 68 170	400 1362 = 0.02); 0.00001 Non-fra Events 0 11 15 71	890 3448 l <sup>2</sup> = 825 ) ailty Total 138 143 180 718	5.6% 100.0% % Weight 4.2% 2.8% 9.3%	1.32 [1.10, 1.59] 1.65 [1.56, 1.74] Risk Ratio M-H, Fixed, 95% CI Not estimable 5.69 [3.15, 10.28] 1.94 [0.94, 4.01] 3.21 [2.35, 4.39]	
McKechnie 2021 Fotal (95% CI) Fotal events feterogeneity: Chi <sup>2</sup> = Fest for overall effect Depression Mututo 2020 Jilmore 2021 Jienchoz 2017 Jiume 2021 Jiu 2021	54 3115 5.70, df : Z = 18.6 Frail Events 0 77 11 54 23	91 4972 = 1 (P 56 (P < Total 12 176 68 170 31	400 1362 = 0.02); 0.00001 Non-fra Events 0 11 15 71 106	890 3448 l <sup>2</sup> = 825 ) ailty Total 138 143 180 718 603	5.6% 100.0% % Weight 4.2% 2.8% 9.3% 3.6%	1.32 [1.10, 1.59] 1.65 [1.56, 1.74] Risk Ratio M-H, Fixed, 95% CI Not estimable 5.69 [3.15, 10.28] 1.94 [0.94, 4.01] 3.21 [2.35, 4.39] 4.22 [3.22, 5.53]	
McKechnie 2021 Total (95% CI) Total events deterogeneity: Chi <sup>2</sup> = Fest for overall effect Depression itudy or Subgroup itudy or Subgroup itudy color illimore 2021 idenchoz 2017 ume 2021 izka 2021	54 3115 5.70, df : Z = 18.6 Frailt Events 0 77 11 54 23 1039	91 4972 = 1 (P 56 (P < Total 12 176 68 170 31 4881	400 1362 = 0.02); 0.00001 Non-fra Events 0 11 15 71 106 140	890 3448 l <sup>2</sup> = 825 ) ailty Total 138 143 180 718 603 2558	5.6% 100.0% % Weight 4.2% 2.8% 9.3% 62.9%	1.32 [1.10, 1.59] 1.65 [1.56, 1.74] Risk Ratio M-H, Fixed, 95% CI Not estimable 1.94 [0.94, 4.01] 3.21 [2.35, 4.39] 4.22 [3.22, 5.53] 3.89 [3.28, 4.61]	
McKechnie 2021 Total events Total events Teterogeneity: Chi <sup>2</sup> = Fest for overall effect Depression tudy or Subgroup trutto 2020 jalmore 2021 into 2021 into 2021 izzka 2021 tizka 2021	54 3115 5.70, df Z = 18.6 Frail Events 0 77 711 54 23 1039 64	91 4972 = 1 (P 66 (P < y Total 12 176 68 170 31 4881 272	400 1362 = 0.02); 0.00001 Non-fra Events 0 11 15 71 106 140 31	890 3448 l <sup>2</sup> = 825 ) ailty Total 138 143 180 718 603 2558 180	5.6% 100.0% % Weight 4.2% 2.8% 9.3% 62.9% 62.9% 12.8%	1.32 [1.10, 1.59] 1.65 [1.56, 1.74] Risk Ratio M-H, Fixed, 95% CI Not estimable 5.69 [3.15, 10.28] 1.94 [0.94, 4.01] 3.21 [2.35, 4.39] 4.22 [3.22, 2.5,33] 3.89 [3.28, 4.61] 3.70 [9.32, 2.01]	
McKechnie 2021 Total events Total events Teterogeneity: Chi <sup>2</sup> = Fest for overall effect Depression tudy or Subgroup trutto 2020 jalmore 2021 into 2021 into 2021 izzka 2021 tizka 2021	54 3115 5.70, df : Z = 18.6 Frailt Events 0 77 11 54 23 1039	91 4972 = 1 (P 56 (P < Total 12 176 68 170 31 4881	400 1362 = 0.02); 0.00001 Non-fra Events 0 11 15 71 106 140	890 3448 l <sup>2</sup> = 825 ) ailty Total 138 143 180 718 603 2558	5.6% 100.0% % Weight 4.2% 2.8% 9.3% 62.9%	1.32 [1.10, 1.59] 1.65 [1.56, 1.74] Risk Ratio M-H, Fixed, 95% CI Not estimable 1.94 [0.94, 4.01] 3.21 [2.35, 4.39] 4.22 [3.22, 5.53] 3.89 [3.28, 4.61]	
McKechnie 2021 <b>Total (95% CI)</b> Total events Heterogeneity: Chi <sup>2</sup> = Test for overall effect	54 3115 5.70, df Z = 18.6 Frail Events 0 77 711 54 23 1039 64	91 4972 = 1 (P 66 (P < y Total 12 176 68 170 31 4881 272	400 1362 = 0.02); 0.00001 Non-fra Events 0 11 15 71 106 140 31	890 3448 l <sup>2</sup> = 825 ) ailty Total 138 143 180 718 603 2558 180 115	5.6% 100.0% % Weight 4.2% 2.8% 9.3% 62.9% 62.9% 12.8%	1.32 [1.10, 1.59] 1.65 [1.56, 1.74] Risk Ratio M-H, Fixed, 95% CI Not estimable 5.69 [3.15, 10.28] 1.94 [0.94, 4.01] 3.21 [2.35, 4.39] 4.22 [3.22, 2.5,33] 3.89 [3.28, 4.61] 3.70 [9.32, 2.01]	
McKechnie 2021 Total (95% CI) Total events feterogeneity: Ch <sup>2</sup> = fest for overall effect Depression Nutdy or Subgroup intuto 2020 intuto 2021 intuto 2021 intu 2021 itzka 2021 etata 2021 tizka 2021 tizka 2021 fotal 99% CI) Total events	54 3115 5.70, df : Z = 18.6 Frail Events 0 77 711 54 23 1039 64 30 1298	91 4972 = 1 (P 66 (P < 77 12 176 68 170 31 4881 272 99 5709	400 1362 = 0.02); 0.00001 Non-fra Events 0 11 15 71 106 140 31 14 388	890 3448 I <sup>2</sup> = 825 ) Total 138 143 143 180 718 603 2558 180 115 4635	5.6% 100.0% % Weight 4.2% 2.8% 9.3% 3.6% 62.9% 12.8% 4.4% 100.0%	1.32 (1.10, 1.59) 1.65 (1.56, 1.74) Risk Ratio Not estimable 5.69 (3.15, 10.28) 1.94 (0.94, 4.01) 3.21 (2.35, 4.39) 4.22 (3.22, 5.53) 3.89 (3.28, 4.61) 1.37 (0.93, 2.01) 2.49 (1.40, 4.42)	
McKechnie 2021 Total (95% CI) Total events feterogeneity: Ch <sup>2</sup> = fest for overall effect Depression Nutdy or Subgroup intuto 2020 intuto 2021 intuto 2021 intu 2021 itzka 2021 etata 2021 tizka 2021 tizka 2021 fotal 99% CI) Total events	54 3115 5.70, df : Z = 18.6 Frail Events 0 77 711 54 23 1039 64 30 1298	91 4972 = 1 (P 66 (P < 77 12 176 68 170 31 4881 272 99 5709	400 1362 = 0.02); 0.00001 Non-fra Events 0 11 15 71 106 140 31 14 388	890 3448 I <sup>2</sup> = 825 ) Total 138 143 180 718 603 2558 180 115 4635	5.6% 100.0% % Weight 4.2% 2.8% 9.3% 3.6% 62.9% 12.8% 4.4% 100.0%	1.32 (1.10, 1.59) 1.65 (1.56, 1.74) Risk Ratio M-H, Fixed, 95% C1 Not estimable 5.69 (3.15, 10.28) 1.94 (0.94, 4.01) 3.21 (2.35, 4.39) 4.22 (3.22, 5.53) 3.89 (3.28, 4.61) 1.37 (0.93, 2.01) 2.49 (1.40, 4.42)	
McKechnie 2021 Total (95% CI) Total events Test for overall effect Depression Tutto 2020 Jimore 2021 Jimore 2021 Jimore 2021 Jia 2021 Jiz ka 2021 Jiz ka 2021 Jiz ka 2021 Total (95% CI)	54 3115 5.70, df : Z = 18.6 Frailt Events 0 77 711 54 23 1039 64 30 1298 32.89, d	91 4972 = 1 (P 6 (P < 3 12 176 68 170 31 4812 99 5709 f = 6 (F	400 1362 = 0.02); 0.00001 Non-fra Events 0 11 15 71 106 140 31 14 388 < < 0.000	890 3448 I <sup>2</sup> = 825 ) ailty Total 138 148 148 148 148 180 718 603 2558 180 115 4635 01); I <sup>2</sup> =	5.6% 100.0% % Weight 4.2% 2.8% 9.3% 3.6% 62.9% 12.8% 4.4% 100.0%	1.32 (1.10, 1.59) 1.65 (1.56, 1.74) Risk Ratio M-H, Fixed, 95% C1 Not estimable 5.69 (3.15, 10.28) 1.94 (0.94, 4.01) 3.21 (2.35, 4.39) 4.22 (3.22, 5.53) 3.89 (3.28, 4.61) 1.37 (0.93, 2.01) 2.49 (1.40, 4.42)	
deckechnie 2021 fortal 995% CI) fortal events feterogeneity: Ch <sup>2</sup> = fest for overall effect Depression Depr	54 3115 5.70, df : Z = 18.6 Frailt Events 0 77 711 54 23 1039 64 30 1298 32.89, d	91 4972 = 1 (P 6 (P < 3 12 176 68 170 31 4812 99 5709 f = 6 (F	400 1362 = 0.02); 0.00001 Non-fra Events 0 11 15 71 106 140 31 14 388 < < 0.000	890 3448 I <sup>2</sup> = 825 ) ailty Total 138 148 148 148 148 180 718 603 2558 180 115 4635 01); I <sup>2</sup> =	5.6% 100.0% % Weight 4.2% 2.8% 9.3% 3.6% 62.9% 12.8% 4.4% 100.0%	1.32 (1.10, 1.59) 1.65 (1.56, 1.74) Risk Ratio M-H, Fixed, 95% C1 Not estimable 5.69 (3.15, 10.28) 1.94 (0.94, 4.01) 3.21 (2.35, 4.39) 4.22 (3.22, 5.53) 3.89 (3.28, 4.61) 1.37 (0.93, 2.01) 2.49 (1.40, 4.42)	
deckechnie 2021 fortal 995% CI) fortal events feterogeneity: Ch <sup>2</sup> = fest for overall effect Depression Depr	54 3115 5.70, df : Z = 18.6 Frailt Events 0 77 711 54 23 1039 64 30 1298 32.89, d	91 4972 = 1 (P 6 (P < 3 12 176 68 170 31 4812 99 5709 f = 6 (F	400 1362 = 0.02); 0.00001 Non-fra Events 0 11 15 71 106 140 31 14 388 < < 0.000	890 3448 I <sup>2</sup> = 825 ) ailty Total 138 148 148 148 148 180 718 603 2558 180 115 4635 01); I <sup>2</sup> =	5.6% 100.0% % Weight 4.2% 2.8% 9.3% 3.6% 62.9% 12.8% 4.4% 100.0%	1.32 (1.10, 1.59) 1.65 (1.56, 1.74) Risk Ratio M-H, Fixed, 95% C1 Not estimable 5.69 (3.15, 10.28) 1.94 (0.94, 4.01) 3.21 (2.35, 4.39) 4.22 (3.22, 5.53) 3.89 (3.28, 4.61) 1.37 (0.93, 2.01) 2.49 (1.40, 4.42)	
deckechnie 2021 fortal 995% CI) fortal events feterogeneity: Ch <sup>2</sup> = fest for overall effect Depression Depr	54 3115 5.70, df : Z = 18.6 Frailt Events 0 77 711 54 23 1039 64 30 1298 32.89, d	91 4972 = 1 (P 6 (P < 3 12 176 68 170 31 4812 99 5709 f = 6 (F	400 1362 = 0.02); 0.00001 Non-fra Events 0 11 15 71 106 140 31 14 388 < < 0.000	890 3448 I <sup>2</sup> = 825 ) ailty Total 138 148 148 148 148 180 718 603 2558 180 115 4635 01); I <sup>2</sup> =	5.6% 100.0% % Weight 4.2% 2.8% 9.3% 3.6% 62.9% 12.8% 4.4% 100.0%	1.32 (1.10, 1.59) 1.65 (1.56, 1.74) Risk Ratio M-H, Fixed, 95% C1 Not estimable 5.69 (3.15, 10.28) 1.94 (0.94, 4.01) 3.21 (2.35, 4.39) 4.22 (3.22, 5.53) 3.89 (3.28, 4.61) 1.37 (0.93, 2.01) 2.49 (1.40, 4.42)	
kckechnie 2021 Total 995K CD Total events teterogeneity: Chi <sup>2</sup> = es teterogeneity: Chi <sup>2</sup> = es teterogeneity: Chi <sup>2</sup> = es teterogeneity: Chi <sup>2</sup> = es teterogeneity: Chi <sup>2</sup> = est for overall effect:	54 3115 5.70, df Z = 18.6 Frail Events 0 77 71 11 54 4 23 1039 64 30 1298 32.89, d Z = 19.0	91 4972 = 1 (P 66 (P < Y Total 12 176 68 170 31 4881 272 99 5709 f = 6 (F <	400 1362 = 0.02); 0.00001 Non-fra Events 0 11 15 5 71 106 140 31 14 388 < 0.0001	890 3448 I <sup>2</sup> = 825 ) ailty Total 138 148 148 148 148 180 718 603 2558 180 115 4635 01); I <sup>2</sup> =	5.6% 100.0% % Weight 4.2% 2.8% 9.3% 3.6% 62.9% 12.8% 4.4% 100.0%	1.32 (1.10, 1.59) 1.65 (1.56, 1.74) Risk Ratio M-H, Fixed, 95% C1 Not estimable 5.69 (3.15, 10.28) 1.94 (0.94, 4.01) 3.21 (2.35, 4.39) 4.22 (3.22, 5.53) 3.89 (3.28, 4.61) 1.37 (0.93, 2.01) 2.49 (1.40, 4.42)	
kckechnie 2021 Total 995K CD Total events teterogeneity: Chi <sup>2</sup> = es teterogeneity: Chi <sup>2</sup> = es teterogeneity: Chi <sup>2</sup> = es teterogeneity: Chi <sup>2</sup> = es teterogeneity: Chi <sup>2</sup> = est for overall effect:	54 3115 5.70, df Z = 18.6 Frail Events 0 77 11 54 23 1039 64 30 1298 32.89, d Z = 19.0 Type of the second secon	91 4972 = 1 (P i6 (P < yy Total 12 176 31 1270 31 2722 99 5709 f = 6 (P < \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	400 1362 = 0.02); 0.00001 Non-fri Events 0 11 15 71 106 140 31 14 388 < 0.0000 0 0 0 0 15 71 106 140 31 140 388 SC	890 <b>3448</b> I <sup>2</sup> = 825 ) <b>ailty</b> <b>Total</b> 138 143 143 143 143 143 143 143 143	5.6% 100.0% % Weight 4.2% 2.8% 9.3% 3.6% 62.9% 12.8% 4.4% 100.0%	1.32 (1.10, 1.59) 1.65 (1.56, 1.74) Risk Ratio M-H, Fixed, 95% (1 Not estimable 5.69 (3.15, 10.28) 1.94 (10.94, 4.01) 3.21 (2.35, 4.39) 3.23 (3.28, 4.61) 3.24 (3.28, 4.29) 3.24 (3.29, 4.29) 3.	
kdecehnie 2021 Total 995K CD Total events teterogeneity: Chi <sup>2</sup> = es teterogeneity: Chi <sup>2</sup> = es teterogeneity: Chi <sup>2</sup> = es terotox 2017 teterotox 2017	54 3115 5.70, df 2 = 18.6 Frail Events 0 77 11 54 23 1039 64 30 1298 32.89, d 2 = 19.0 Frail Fra	91 4972 = 1 (P i6 (P < y Total 122 176 68 170 31 4881 272 99 5709 f = 6 (P < \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	400 1362 = 0.02); 0.00001 Non-frr Events 0 11 15 71 140 311 14 388 < 0.000 0.00001 SC Non-frr	890 <b>3448</b> l <sup>2</sup> = 825 ) <b>ailty</b> <b>Total</b> 138 143 143 160 718 603 2558 4635 4635 91); l <sup>2</sup> =	5.6% 100.0% % Weight 4.2% 4.2% 2.8% 9.3% 62.9% 12.8% 4.4% 82%	1.32 (1.10, 1.59) 1.65 (1.56, 1.74) Risk Ratio M-H, Fixed, 535C1 Net Simable Net Simable 1.04 (0.94, 4.01) 3.21 (2.35, 4.39) 1.34 (0.94, 4.01) 3.22 (2.25, 5.33) 3.89 (3.28, 4.61) 2.49 (1.40, 4.42) 3.47 (3.06, 3.95) Risk Ratio	
Ackechnie 2021 Total 995K CD) Total events teterogeneity: Chi <sup>2</sup> = e tets for overall effect Depression tudy or Subgroup trutto 2020 Jimore 2021 tenchoz 2017 tune 2021 tenchoz 2021 tune	54 3115 5.70, df Z = 18.6 Frail Events 0 77 11 11 54 23 1039 64 30 1298 32.89, d Z = 19.0 Frail Events Frail Frail Events Frail Frail Frail Events Frail	91 4972 4972 4972 4972 407 10 12 176 68 170 31 170 68 170 31 272 99 5709 f = 6 (F < 5709 f = 7 (F  5709 f = 7 (F  5700) f = 7 (F	400 1362 = 0.02); 0 0 0 11 15 71 106 140 31 14 388 < 0.00001 	890 <b>3448</b> I <sup>2</sup> = 829 ) <b>ailty</b> <b>Total</b> 138 143 138 180 718 6635 4635 01); I <sup>2</sup> = <b>ailty</b> <b>Total</b>	5.6% 100.0% Weight 4.2% 2.8% 4.2% 82% 82% Weight	1.32 (1.10, 1.59) 1.65 (1.56, 1.74) Risk Ratio M-H, Fixed, 95% (1 Not estimable 1.94 (10,94, 4.01) 2.31 (2.35, 4.39) 4.28 (3.22, 5.51) 3.21 (2.35, 4.39) 4.28 (3.22, 5.51) 3.24 (2.35, 4.39) 4.29 (1.40, 4.42) 3.47 (3.06, 3.95) Risk Ratio M-H, Fixed, 95% (1	
kckechnie 2021 Total 995K CD; Total 995K CD; Total events teterogeneity: Chi <sup>2</sup> = e set for overall effect Depression ktudy or Subgroup trutto 2020 imme 2021 imme 2021 imme 2021 itzka 2021 etait 2021 total 955K CD; Total 95	54 3115 5.70, df Z = 18.6 Frail Events 0 0 77 11 54 23 1039 64 30 1298 32.89, df Z = 19.0 Frail Events 1298 32.89, df Z = 18.6 8 1039 10	91 4972 4972 10 10 10 10 10 10 10 10 10 10	400 1362 = 0.02); Non-frr Events 0 11 15 71 106 140 318 4 < 0.0001 SC Non-fr 72 14 5 5 6 0 0 0 0 0 0 0 0 0 0 0 0 0	890 <b>3448</b> l <sup>2</sup> = 829 ) <b>ailty</b> <b>Total</b> 138 143 180 115 <b>4635</b> (1); l <sup>2</sup> = (1); l <sup>2</sup>	5.6% 100.0% % Weight 4.2% 2.8% 4.2% 9.3% 3.6% 4.4% 82% 82%	1.32 (1.10, 1.59) 1.65 (1.56, 1.74) Risk Ratio M-H, Fixed, 555 (1) Not estimable 514 (15, 10, 22) 1.32 (12, 23, 4.30) 1.32 (12, 23, 4.30) 1.37 (1.95, 2.01) 2.49 (1.40, 4.42) 3.47 (3.06, 3.95) Risk Ratio M-H, Fixed, 955 (1) 2.01 (0.66, 4.71)	
Ackechnie 2021 Total 995K CD) Total events teterogeneity: Chi <sup>2</sup> = est for overall effect Depression tudy or Subgroup trutto 2020 Jimore 2021 tenchoz 2017 tune 2021 tenchoz 2017 tenchoz 20	54 3115 5.70, df Z = 18.6 Prail Events 0 0 77 11 54 4 32.89, d. 2 2 1298 32.89, d. 2 2 19.0 1298 52.6 1.2 1298 52.6 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2	91 4972 = 1 (P 66 (P < 77 12 176 68 87 170 170 170 170 170 170 170 17	400 1362 = 0.02); 0 0.00001 Non-fr Events 0 11 15 71 106 14 388 388 < 0.000 0.00001 31 14 56C Non-fr Events 9 9 21	890 <b>3448</b> I <sup>2</sup> = 829 ) ailty <u>Total</u> 138 143 180 718 180 718 180 718 180 180 718 180 119 <b>4635</b> ) ) ) I) I <sup>2</sup> = 9 <b>4635</b> I) I) II II II II II II II II	5.6% 100.0% % Weight 4.2% 2.8% 9.3% 62.9% 12.8% 62.9% 12.8% 82% 100.0% 82%	1.32 (1.10, 1.59) 1.65 (1.56, 1.74) Risk Ratio M-H, Fixed, 95% C1 Not estimable 1.94 (10.94, 4.01) 3.21 (2.35, 4.39) 4.22 (3.22, 5.31) 3.21 (2.35, 4.39) 4.22 (3.22, 5.31) 3.21 (2.35, 4.39) 4.22 (3.24, 5.31) 3.24 (2.34, 4.32) 2.49 (1.40, 4.42) 3.47 (3.06, 3.95) Risk Ratio M-H, Fixed, 95% C1 2.01 (0.66, 4.71) 1.13 (0.43, 3.00)	
kckechnie 2021 Total 995K CD) Total events teterogeneity: Chi <sup>2</sup> = es teterogeneity: Chi <sup>2</sup> = es tetorovarial effect Depression tuto 2020 timote 2021 timote 2021 timote 2021 tiztka 2021 ti	54 3115 5.7.0, df Fraili Events 0 77 11 54 30 1298 32.89, d 2 Z = 19.0 1298 32.89, d Z Z = 19.0 1298 8 4 4 4 2 8 8 8 4 2 2 2 3 2 3 2 3 2 3 3 3 3 3 3 3 3 3 3 3 3 3	91 4972 4972 10 10 10 10 10 10 10 10 10 10	400 1362 = 0.02); 0.00001 Non-frr Events 0 11 15 71 106 0 140 318 388 < 0.000 0.00001 40 56C Non-frr Events 9 21 14	890 <b>3448</b> l <sup>2</sup> = 829 ) <b>ailty</b> <b>Total</b> 138 143 180 115 <b>4635</b> (1); l <sup>2</sup> = (1); l <sup>2</sup>	5.6% 100.0% % Weight 4.2% 2.8% 4.4% 9.3% 3.6% 4.4% 100.0% 82% Weight 1.4% 1.4%	1.32 (1.10, 1.59) 1.65 (1.56, 1.74) Risk Ratio M-H, Fixed, 55X (T) Not estimable 5.13 (1.5), 10.28) 1.32 (1.23, 4.30) 1.32 (1.23, 4.30) 1.37 (1.93, 2.01) 2.49 (1.40, 4.42) 3.47 (3.06, 3.95) Risk Ratio M-H, Fixed, 95X (C) 2.01 (0.66, 4.71) 1.13 (0.43, 3.00) 1.64 (0.42, 6.40)	
deckechnie 2021 fotal 99% CD) fotal events feterogeneity: Chi <sup>2</sup> = e set for overall effect Depression tudy or Subgroup trutto 2020 ilimore 2021 isizka 2021 isizka 2021 isizka 2021 total events feterogeneity: Chi <sup>2</sup> = fest for overall effect Study or Subgroup Mysta 2021 Study or Subgroup Mysta 2021 Study or Subgroup Mysta 2021 Study or Subgroup	54 3115 5.70, df Fraili Events Events 1039 64 30 1298 32.89, d 32.89, d 2 = 19.0 1298 82.89, d 2 = 19.0 1298 84 2 = 37 37	91 4972 = 1 (P f 6 (P < yy Total 12 176 6 170 31 4 88 170 31 4 88 170 99 5709 f = 6 (P y ty Total 31 31 4 88 170 31 31 4 88 170 31 31 31 31 4 88 170 31 31 31 31 31 31 31 31 31 31	400 1362 = 0.02); 0.000001 Non-frefs 0 11 15 71 140 318 388 388 388 8 0 0 0 0 0 0 0 0 0 0 0 0 0	890 <b>3448</b> I <sup>2</sup> = 829 ) ailty <b>Total</b> 138 143 180 718 160 1558 4635 4635 01); I <sup>2</sup> = ) ailty <b>Total</b> 100 115 4635 01); I <sup>2</sup> = 100 100 100 100 100 100 100 10	5.6% 100.0% % Weight 4.2% 2.8% 9.3% 3.6% 62.9% 82% 100.0% 82% Weight 10.0% 82%	1.32 (1.10, 1.59) 1.65 (1.56, 1.74) Risk Ratio M-H, Fixed, 95% C1 Not estimable 5.69 (3.15, 10.28) 1.94 (10.94, 4.01) 3.24 (2.35, 4.39) 4.22 (3.24, 5.43) 4.22 (3.24, 5.43) 4.22 (3.24, 5.43) 3.47 (3.06, 3.95) Risk Ratio M-H, Fixed, 95% C1 2.01 (0.66, 4.71) 1.13 (0.04, 3.00) 1.64 (0.42, 6.40) 1.13 (0.04, 3.00)	
deckechnie 2021 fotal 99% CD) fotal events feterogeneity: Chi <sup>2</sup> = e set for overall effect Depression tudy or Subgroup trutto 2020 ilimore 2021 isizka 2021 isizka 2021 isizka 2021 total events feterogeneity: Chi <sup>2</sup> = fest for overall effect Study or Subgroup Mysta 2021 Study or Subgroup Mysta 2021 Study or Subgroup Mysta 2021 Study or Subgroup	54 3115 5.7.0, df Fraili Events 0 77 11 54 30 1298 32.89, d 2 Z = 19.0 1298 32.89, d Z Z = 19.0 1298 8 4 4 4 2 8 8 8 4 2 2 2 3 2 3 2 3 2 3 3 3 3 3 3 3 3 3 3 3 3 3	91 4972 = 1 (P < 10 (P < 12 1766 (P < 12 1766 (P < 12 1767 (P < 13 1 12 1767 (P < 14 881 170 31 170 31 170 (P < 14 99 (P < 5709 (P < 5700 (P </td <td>400 1362 = 0.02); 0.00001 Non-frr Events 0 11 15 71 106 0 140 318 388 &lt; 0.000 0.00001 40 56C Non-frr Events 9 21 14</td> <td>890 <b>3448</b>  l<sup>2</sup> = 829 ) <b>aility</b> <b>Total</b> 138 143 180 0115 <b>4635</b> (11); l<sup>2</sup> = ) <b>aility</b> <b>Total</b> <b>6</b>03 115 <b>4635</b> (11); l<sup>2</sup> = (11) (11); l<sup>2</sup> = (11) (11); l<sup>2</sup> = (11) (11); l<sup>2</sup> = (11) (11); l<sup>2</sup> = (11) (11); l<sup>2</sup> = (11) (11); l<sup>2</sup> = (11); l<sup>2</sup> = (</td> <td>5.6% 100.0% % Weight 4.2% 2.8% 9.3% 3.6% 62.9% 82% 100.0% 82% Weight 10.0% 82%</td> <td>1.32 (1.10, 1.59) 1.65 (1.56, 1.74) Risk Ratio M-H, Fixed, 55X (T) Not estimable 5.13 (1.5), 10.28) 1.32 (1.23, 4.30) 1.32 (1.23, 4.30) 1.37 (1.93, 2.01) 2.49 (1.40, 4.42) 3.47 (3.06, 3.95) Risk Ratio M-H, Fixed, 95X (C) 2.01 (0.66, 4.71) 1.13 (0.43, 3.00) 1.64 (0.42, 6.40)</td> <td></td>	400 1362 = 0.02); 0.00001 Non-frr Events 0 11 15 71 106 0 140 318 388 < 0.000 0.00001 40 56C Non-frr Events 9 21 14	890 <b>3448</b>  l <sup>2</sup> = 829 ) <b>aility</b> <b>Total</b> 138 143 180 0115 <b>4635</b> (11); l <sup>2</sup> = ) <b>aility</b> <b>Total</b> <b>6</b> 03 115 <b>4635</b> (11); l <sup>2</sup> = (11) (11); l <sup>2</sup> = (11); l <sup>2</sup> = (	5.6% 100.0% % Weight 4.2% 2.8% 9.3% 3.6% 62.9% 82% 100.0% 82% Weight 10.0% 82%	1.32 (1.10, 1.59) 1.65 (1.56, 1.74) Risk Ratio M-H, Fixed, 55X (T) Not estimable 5.13 (1.5), 10.28) 1.32 (1.23, 4.30) 1.32 (1.23, 4.30) 1.37 (1.93, 2.01) 2.49 (1.40, 4.42) 3.47 (3.06, 3.95) Risk Ratio M-H, Fixed, 95X (C) 2.01 (0.66, 4.71) 1.13 (0.43, 3.00) 1.64 (0.42, 6.40)	
kdecehnie 2021 Total 995% CD Total 995% CD Total 995% CD Total 996% teterogeneity: Chi <sup>2</sup> = e set for overall affect Depression tudy or Subgroup tudy or Subgroup tudy or Subgroup tital 2021 tital 20	54 3115 5.70, df Fraili Events Events 1039 64 30 1298 32.89, d 32.89, d 2 = 19.0 1298 82.89, d 2 = 19.0 1298 84 2 = 37 77 10 10 10 10 10 10 10 10 10 10	91 4972 = 1 (P i6 (P < i7 12 176 68 170 0 31 4881 272 99 5709 f = 6 (F <b>SECUS</b> ty Total 30 (P < 5709 12 12 170 68 99 99 (P < 5709 12 12 170 12 170 12 170 170 170 172 170 172 170 172 170 172 170 172 170 172 170 172 170 172 170 172 170 172 170 172 170 172 170 172 170 172 170 172 170 170 172 170 170 172 170 172 170 170 170 170 170 170 170 170	400 1362 = 0.02); 0.000001 Non-frefs 0 11 15 71 140 318 388 388 388 8 0 0 0 0 0 0 0 0 0 0 0 0 0	890           3448           j² = 825           )           ailty           Total           138           143           180           115           4635           4635           401); l² =           )           railty           Total           68           137           718           68           137           138           94           288	5.6% 5.6% Weight 4.2% 2.8% 4.2% 2.8% 4.4% 4.4% 82% Weight 3.77% 2.8% 100.0% 82%	L 22 (1.10, 1.59) 1.65 (1.56, 1.74) Risk Ratio M-H, Fixed, 535C4 1.04 (10,94, 4.01) 3.21 (2.35, 4.39) 4.22 (3.22, 5.53) 3.89 (3.28, 4.61) 3.47 (3.06, 3.95) Risk Ratio M-H, Fixed, 935C4 2.49 (1.40, 4.42) 3.47 (3.06, 3.95) Risk Ratio M-H, Fixed, 935C4 1.13 (0.76, 1.78) 1.13 (0.76, 1.78) 1.14 (1.20, 1.73)	
tekechnie 2021 total 995K CI) total events teterogenehy: Chi <sup>2</sup> = e set for overall effect Depression tudy or Subgroup rutto 2020 imme 2021 inder 2021 total 995K CI) otal events Respirator teterogenehy: Chi <sup>2</sup> = e set for overall effect Respirator tudy or Subgroup typesta 2021 umg 2020 tudy or Subgroup typesta 2021 umg 2020 tudy or Subgroup typesta 2021 umg 2020 tumg 2	54 3115 5.70, df Z = 18,6 77 11 1298 32,89, d 32,89, d 32,89, d 23,89, d 23,89, d 23,89, d 23,89, d 23,89, d 24,23 24,23 24,24 24,23 24,24 24,2	91 4972 = 1 (P f 6 (P < yy Total 12 176 6 170 31 4 88 170 31 4 88 170 99 5709 f = 6 (P y ty Total 31 31 4 88 170 31 31 4 88 170 31 31 31 31 4 88 170 31 31 31 31 31 31 31 31 31 31	400 1362 = 0.02); 0.00001 Non-frr Events 0 11 15 71 15 71 14 388 8 < 0.00001 31 14 388 Sec Non-fr 11 14 388 14 28 14 28 14 28 21 21 21 21 21 21 21 21 21 21	890 <b>3448</b> I <sup>2</sup> = 829 ) ailty <b>Total</b> 138 143 180 718 160 1558 4635 4635 01); I <sup>2</sup> = ) ailty <b>Total</b> 100 115 4635 01); I <sup>2</sup> = 100 100 100 100 100 100 100 10	5.6% 5.6% Weight 4.2% 2.8% 4.2% 2.8% 4.4% 4.4% 82% Weight 3.77% 2.8% 100.0% 82%	1.32 (1.10, 1.59) 1.65 (1.56, 1.74) Risk Ratio M-H, Fixed, 95% C1 Not estimable 5.69 (3.15, 10.28) 1.94 (10.94, 4.01) 3.24 (2.35, 4.39) 4.22 (3.24, 5.43) 4.22 (3.24, 5.43) 4.22 (3.24, 5.43) 3.47 (3.06, 3.95) Risk Ratio M-H, Fixed, 95% C1 2.01 (0.66, 4.71) 1.13 (0.04, 3.00) 1.64 (0.42, 6.40) 1.13 (0.04, 3.00)	
deckechnie 2021 fotal 99% CD) fotal events feterogeneity: Chi <sup>2</sup> = e set for overall effect Depression tudy or Subgroup trutto 2020 ilimore 2021 isizka 2021 isizka 2021 isizka 2021 total events feterogeneity: Chi <sup>2</sup> = fest for overall effect Study or Subgroup Mysta 2021 Study or Subgroup Mysta 2021 Study or Subgroup Mysta 2021 Study or Subgroup	54 3115 5.70, df df Events Events 0 0 77 11 14 20 32.89, df 32.89, df 22 19.0 1298 8 22 19.0 1298 8 22 19.0 1298 1297 12988 1298 12988 12988 12988 12988 12988 12988 1298	91 4972 = 1 (P i6 (P < y Total 126 68 170 31 4881 272 5709 f = 6 (P 99 (P < SCCC ty Total 30 272 486	400 1362 = 0.02): 0.00001 Non-frr Events 0 0 11 15 71 106 6 0 318 388 388 388 388 9 9 21 14 12 10 10 10 10 10 10 10 10 10 10	890           3448           j² = 825           )           ailty           Total           683           138           4635           4635           01); l² =           )           ailty           Total           68           137           68           137           288           725	5.6% 5.6% Weight 4.2% 2.8% 4.2% 2.8% 62.9% 4.4% 82% Weight 3.7% 2.8% 100.0% 12.0% 12.0% 10.0%	L 22 (1.10, 1.59) 1.65 (1.56, 1.74) Risk Ratio M-H, Fixed, 535C4 1.04 (10,94, 4.01) 3.21 (2.35, 4.39) 4.22 (3.22, 5.53) 3.89 (3.28, 4.61) 3.47 (3.06, 3.95) Risk Ratio M-H, Fixed, 935C4 2.49 (1.40, 4.42) 3.47 (3.06, 3.95) Risk Ratio M-H, Fixed, 935C4 1.13 (0.76, 1.78) 1.13 (0.76, 1.78) 1.14 (1.20, 1.73)	

Figure 3. The forest plots of the impact of lifestyle and comorbidities on frailty.

need to be further explored; second, we did not further compare the difference in frailty between community-dwelling elderly individuals and elderly individuals in the hospital. Finally, more research is needed regarding interventions for this form of frailty.

### 5. Conclusion

The final results demonstrated the following: among the ageing population, older age, low BMI, female sex, living alone, low levels of exercise, polypharmacy, education, smoking, drinking, malnutrition, and low vitamin D levels had significant relationships with frailty; elderly adults with diabetes, hearing dysfunction, cognitive impairment, poor sleep, a history of falls, pain, and depression were at a higher risk of frailty than those without those comorbidities.

#### Author contributions

Data curation: Diping Wu. Investigation: Diping Wu, Xinrui Wang. Methodology: Xinrui Wang. Supervision: Diping Wu, Jiji Hu. Writing – original draft: Jiji Hu.

#### References

- Qiu Y, Li G, Wang X, et al. Prevalence of cognitive frailty among community-dwelling older adults: a systematic review and meta-analysis. Int J Nurs Stud. 2000;125:104112.
- [2] Morley JE, Vellas B, van Kan GA, et al. Frailty consensus: a call to action. J Am Med Dir Assoc. 2013;14:392–7.
- [3] Bagshaw SM, Stelfox HT, Johnson JA, et al. Long-term association between frailty and health-related quality of life among survivors of critical illness: a prospective multicenter cohort study. Crit Care Med. 2015;43:973–82.
- [4] Tang JY, Luo H, Tse M, et al. The relationship between insomnia symptoms and frailty in community-dwelling older persons: a path analysis. Sleep Med. 2021;84:237–43.
- [5] Poli S, Cella A, Puntoni M, et al. Frailty is associated with socioeconomic and lifestyle factors in community-dwelling older subjects. Aging Clin Exp Res. 2017;29:721–8.
- [6] Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol Med Sci. 2001;56:146–56.
- [7] Rockwood K, Mitnitski A. Frailty defined by deficit accumulation and geriatric medicine defined by frailty. Clin Geriatr Med. 2011;27:17–26.
- [8] Arts MHL, van den Berg KS, Marijnissen RM, et al. Frailty as a predictor of mortality in late-life depression: a prospective clinical cohort study. J Clin Psychiatry. 2021;82:20m13277.
- [9] Ayesta A, Valero Masa MJ, Vidán MT, et al. Prevalence and characterization of frailty, depression, and cognitive impairment in patients

listed for heart transplantation: results of the FELICITAR prospective registry. Clin Transplant. 2021;35:e14391.

- [10] Brutto OH, Mera RM, Peinado CD, et al. Frailty and risk of falls in community-dwelling older adults living in a rural setting. The Atahualpa Project. J Frailty Aging. 2020;9:150–4.
- [11] Chen WY, Liu CY, Shih CC, et al. Factors associated with frailty in patients undergoing cardiac surgery: a longitudinal study. J Cardiovasc Nurs. 2022;37:204–12.
- [12] Fan J, Liu C-Y, Wang Q, et al. Association of insomnia and multidimensional frailty in community-dwelling older adults: a cross-sectional survey. J Clin Nurs. 2021;31:167–73.
- [13] Gilmore N, Kehoe L, Bauer J, et al. The relationship between frailty and emotional health in older patients with advanced cancer. Oncologist. 2021;26:e2181–91.
- [14] Gomes CDS, Guerra RO, Wu YY, et al. Social and economic predictors of worse frailty status occurrence across selected countries in North and South America and Europe. Innov Aging. 2018;2:igy037.
- [15] Henchoz Y, Büla C, Guessous I, et al. Association between physical frailty and quality of life in a representative sample of community-dwelling Swiss older people. J Nutr Health Aging. 2017;21:585–92.
- [16] Hong X, Yan J, Xu L, et al. Relationship between nutritional status and frailty in hospitalized older patients. Clin Interv Aging. 2019;14:105–11.
- [17] Ikeda T, Tsuboya T, Aida J, et al. Income and education are associated with transitions in health status among community-dwelling older people in Japan: the JAGES cohort study. Fam Pract. 2019;36:713–22.
- [18] Jang HY, Kim J-H. Factors associated with frailty according to gender of older adults living alone. Healthcare (Basel). 2021;9:475.
- [19] Jiao J, Wang Y, Zhu C, et al. Prevalence and associated factors for frailty among elder patients in China: a multicentre cross-sectional study. BMC Geriatr. 2020;20:100.
- [20] Jung H, Kim M, Lee Y, et al. Prevalence of physical frailty and its multidimensional risk factors in Korean community-dwelling older adults: findings from Korean frailty and aging cohort study. Int J Environ Res Public Health. 2020;17:7883.
- [21] Kim J, Lee Y, Won CW, et al. Dietary patterns and frailty in older Korean adults: results from the Korean frailty and aging cohort study. Nutrients. 2021;13:601.
- [22] Kume Y, Takahashi T, Itakura Y, et al. Polypharmacy and lack of joy are related to physical frailty among Northern Japanese community-dwellers from the ORANGE cohort study. Gerontology. 2021;67:184–93.
- [23] Lee D, Kim M, Won CW. Common and different characteristics among combinations of physical frailty and sarcopenia in community-dwelling older adults: the Korean frailty and aging cohort study. Geriatr Gerontol Int. 2022;22:42–9.
- [24] Lee JS, Auyeung TW, Leung J, et al. Long sleep duration is associated with higher mortality in older people independent of frailty: a 5-year cohort study. J Am Med Dir Assoc. 2014;15:649–54.
- [25] Liang H, Li X, Lin X, et al. The correlation between nutrition and frailty and the receiver operating characteristic curve of different nutritional indexes for frailty. BMC Geriatr. 2021;21:619.
- [26] Liu M, Hou T, Nkimbeng M, et al. Associations between symptoms of pain, insomnia and depression, and frailty in older adults: a cross-sectional analysis of a cohort study. Int J Nurs Stud. 2021;117:103873.
- [27] McKechnie DGJ, Papacosta AO, Lennon LT, et al. Associations between inflammation, cardiovascular biomarkers and incident frailty: the British Regional Heart Study. Age Ageing. 2021;50:1979–87.
- [28] Moradell A, Fernández-García ÁI, Navarrete-Villanueva D, et al. Functional frailty, dietary intake, and risk of malnutrition. Are nutrients involved in muscle synthesis the key for frailty prevention? Nutrients. 2021;13:1231.
- [29] Okamura T, Sugiyama M, Inagaki H, et al. Depressed mood and frailty among older people in Tokyo during the COVID-19 pandemic. Psychogeriatrics. 2021;21:892–901.
- [30] Oyon J, Serra-Prat M, Ferrer M, et al. Psychosocial factors associated with frailty in the community-dwelling aged population with depression. A cross-sectional study. Aten Primaria. 2021;53:102048.

- [31] Ozsoy G, Ates Bulut E, Gurpinar B, et al. Determination of an Optimal Frailty Cutoff Score of Tilburg Frailty Indicator and Frailty Associated Factors in Community-Dwelling Turkish Older Adults. Ann Geriatr Med Res. 2021;25:294–300.
- [32] Rizka A, Indrarespati A, Dwimartutie N, et al. Frailty among older adults living in nursing homes in Indonesia: prevalence and associated factors. Ann Geriatr Med Res. 2021;25:93–7.
- [33] Setiati S, Soejono CH, Harimurti K, et al. Frailty and its associated risk factors: first phase analysis of multicentre Indonesia longitudinal aging study. Front Med (Lausanne). 2021;8:658580.
- [34] Sharma Y, Avina P, Ross E, et al. Nutritional risk assessed by the malnutrition universal screening tool as a predictor of frailty in acutely hospitalised older patients: an observational study. Asia Pac J Clin Nutr. 2021;30:185–91.
- [35] Valdiviesso R, Azevedo LF, Moreira E, et al. Frailty phenotype and associated nutritional factors in a sample of Portuguese outpatients with heart failure. Nutr Metab Cardiovasc Dis. 2021;31:2391–7.
- [36] Wang HY, Zhang M, Sun X. Sex-specific association between socioeconomic status, lifestyle, and the risk of frailty among the elderly in China. Front Med (Lausanne). 2021;8:775518.
- [37] Xu L, Zhang J, Shen S, et al. Clinical frailty scale and biomarkers for assessing frailty in elder inpatients in China. J Nutr Health Aging. 2021;25:77–83.
- [38] Yang L, Jiang Y, Xu S, et al. Evaluation of frailty status among older people living in urban communities by Edmonton Frail Scale in Wuhu, China: a cross-sectional study. Contemp Nurse. 2018;54:630–9.
- [39] Yuan L, Zhang X, Guo N, et al. Prevalence of cognitive impairment in Chinese older inpatients and its relationship with 1-year adverse health outcomes: a multi-center cohort study. BMC Geriatr. 2021;21:595.
- [40] Zhao Y, Lin T, Hou L, et al. Association between geriatric nutritional risk index and frailty in older hospitalized patients. Clin Interv Aging. 2021;16:1241–9.
- [41] Moreno-Tamayo K, Manrique-Espinoza B, Rosas-Carrasco O, et al. Sleep complaints are associated with frailty in Mexican older adults in a rural setting. Geriatr Gerontol Int. 2017;17:2573–8.
- [42] Green, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.4 (updated March 2011). The Cochrane Collaboration; 2011;11:11–5.
- [43] Moher D, Liberati A, Tetzlaff J, et al; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:658.
- [44] Lahousse L, Maes B, Ziere G, et al. Adverse outcomes of frailty in the elderly: the Rotterdam study. Eur J Epidemiol. 2014;29:419–27.
- [45] Gutierrez-Robledo LM, Avila-Funes JA. How to include the social factor for determining frailty? J Frailty Aging. 2012;1:13–7.
- [46] Herr M, Robine J-M, Aegerter P, et al. Contribution of socioeconomic position over life to frailty differences in old age: comparison of lifecourse models in a French sample of 2350 old people. Ann Epidemiol. 2015;25:674–80.
- [47] Jung KH, Yang O, Lee YK, et al. Analysis of the Survey of Living Conditions and Welfare Needs of Korean Older Persons. Sejong, Korea: Korea Institute for Health and Social Affairs; 2017;15:12–22.
- [48] Burton JK, Stewart J, Blair M, et al. Prevalence and implications of frailty in acute stroke: systematic review & meta-analysis. Age Ageing. 2022;51:afac064.
- [49] Gallo L, Gallo M, Augustine H, et al. Assessing patient frailty in plastic surgery: a systematic review. J Plast Reconstr Aesthet Surg. 2022;75:579–85.
- [50] Liu CY, Gong N, Liu W. The association between preoperative frailty and postoperative delirium: a systematic review and meta-analysis. J Perianesth Nurs. 2020;37:53–62.
- [51] Hajek A, Kretzler B, König HH. Relationship between personality factors and frailty. A systematic review. Arch Gerontol Geriatr. 2021;97:104508.